FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1997966062> ?p ?o ?g. }

• W1997966062 abstract "Objective: Anti-HER2 therapy is considered to be important for gastric cancer as well as breast cancer. In a previous study, we showed the combinational efficacy of trastuzumab and pertuzumab (an anti-HER2 antibody which binds a different HER2 domain from trastuzumab) in HER2-positive gastric cancer models (AACR, 2010). In the present study, we investigated the usefulness of a HER2 antibody-cytotoxic drug conjugate, trastuzumab-DM1 (T-DM1) as monotherapy and in combination with pertuzumab for HER2-positive gastric cancer as a novel therapy. Methods: A HER2 over-expressing human gastric cancer, NCI-N87 mouse xenograft model was used for examining the efficacy. T-DM1 was administered intravenously once every 3 weeks. Pertuzumab was administered intra-peritoneally once a week. Tumor growth inhibition (TGI) after 6 weeks of treatment was determined from tumor volume measurements. Apoptosis activity was measured with the activity of caspase 3/7. To measure ADCC activity, a real-time cell analyzer was used. Results: T-DM1 (1.25, 2.5, 5, 10, 20, 40 or 80 mg/kg) as monotherapy showed tumor growth inhibition dose-dependently in the NCI-N87 model. The maximum effective dose was 10 mg/kg and TGI on day 42 after treatment started was 113%. T-DM1 (5 mg/kg) in combination with pertuzumab (40 mg/kg) in the NCI-N87 model showed significantly potent anti-tumor activity with a TGI of 113%. Both T-DM1 and pertuzumab as monotherapies showed significant anti-tumor activity, their TGI were 79% and 47%, respectively. To examine the mechanism of action of the combination of T-DM1 and pertuzumab, we analyzed apoptosis of NCI-N87 cells after treatment with T-DM1, pertuzumab or both under stimulation of EGF or heregulin. 24 h after treatment, the combination group had significantly enhanced caspase 3/7 activity compared with the monotherapy groups. We also examined ADCC activity of these agents. Both T-DM1 and pertuzumab showed ADCC activity and that activity was enhanced by the combination. Conclusion: In this study, we showed that T-DM1 as monotherapy has significant anti-tumor activity in a mice model of HER2-positive gastric cancer. Furthermore, combining T-DM1 with pertuzumab significantly enhanced the anti-tumor activity compared with the efficacy of each agent used in monotherapy. The mechanism of this combination might be the potentiation of apoptosis induction and ADCC activity. The present study suggests that T-DM1 as monotherapy and in combination with pertuzumab would provide benefit for patients with HER2-positive gastric cancers. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1761. doi:10.1158/1538-7445.AM2011-1761" @default.
• W1997966062 created "2016-06-24" @default.
• W1997966062 creator A5044650735 @default.
• W1997966062 creator A5068834994 @default.
• W1997966062 date "2011-04-15" @default.
• W1997966062 modified "2023-09-26" @default.
• W1997966062 title "Abstract 1761: Anti-tumor activity of trastuzumab-DM1 in combination with pertuzumab in a gastric cancer model" @default.
• W1997966062 doi "https://doi.org/10.1158/1538-7445.am2011-1761" @default.
• W1997966062 hasPublicationYear "2011" @default.
• W1997966062 type Work @default.
• W1997966062 sameAs 1997966062 @default.
• W1997966062 citedByCount "0" @default.
• W1997966062 crossrefType "proceedings-article" @default.
• W1997966062 hasAuthorship W1997966062A5044650735 @default.
• W1997966062 hasAuthorship W1997966062A5068834994 @default.
• W1997966062 hasConcept C121608353 @default.
• W1997966062 hasConcept C126322002 @default.
• W1997966062 hasConcept C143998085 @default.
• W1997966062 hasConcept C159654299 @default.
• W1997966062 hasConcept C203014093 @default.
• W1997966062 hasConcept C2776999253 @default.
• W1997966062 hasConcept C2779786085 @default.
• W1997966062 hasConcept C2781164504 @default.
• W1997966062 hasConcept C40677261 @default.
• W1997966062 hasConcept C530470458 @default.
• W1997966062 hasConcept C542903549 @default.
• W1997966062 hasConcept C71924100 @default.
• W1997966062 hasConcept C98274493 @default.
• W1997966062 hasConceptScore W1997966062C121608353 @default.
• W1997966062 hasConceptScore W1997966062C126322002 @default.
• W1997966062 hasConceptScore W1997966062C143998085 @default.
• W1997966062 hasConceptScore W1997966062C159654299 @default.
• W1997966062 hasConceptScore W1997966062C203014093 @default.
• W1997966062 hasConceptScore W1997966062C2776999253 @default.
• W1997966062 hasConceptScore W1997966062C2779786085 @default.
• W1997966062 hasConceptScore W1997966062C2781164504 @default.
• W1997966062 hasConceptScore W1997966062C40677261 @default.
• W1997966062 hasConceptScore W1997966062C530470458 @default.
• W1997966062 hasConceptScore W1997966062C542903549 @default.
• W1997966062 hasConceptScore W1997966062C71924100 @default.
• W1997966062 hasConceptScore W1997966062C98274493 @default.
• W1997966062 hasLocation W19979660621 @default.
• W1997966062 hasOpenAccess W1997966062 @default.
• W1997966062 hasPrimaryLocation W19979660621 @default.
• W1997966062 hasRelatedWork W1550691709 @default.
• W1997966062 hasRelatedWork W1651921929 @default.
• W1997966062 hasRelatedWork W2010941192 @default.
• W1997966062 hasRelatedWork W2032198895 @default.
• W1997966062 hasRelatedWork W2041032730 @default.
• W1997966062 hasRelatedWork W2060974366 @default.
• W1997966062 hasRelatedWork W2093602392 @default.
• W1997966062 hasRelatedWork W2115100262 @default.
• W1997966062 hasRelatedWork W2240495935 @default.
• W1997966062 hasRelatedWork W2313574080 @default.
• W1997966062 hasRelatedWork W2326192200 @default.
• W1997966062 hasRelatedWork W2562310657 @default.
• W1997966062 hasRelatedWork W2590648077 @default.
• W1997966062 hasRelatedWork W2591273445 @default.
• W1997966062 hasRelatedWork W2673643310 @default.
• W1997966062 hasRelatedWork W2686057078 @default.
• W1997966062 hasRelatedWork W2943894624 @default.
• W1997966062 hasRelatedWork W2955316200 @default.
• W1997966062 hasRelatedWork W2999980400 @default.
• W1997966062 hasRelatedWork W3212337109 @default.
• W1997966062 isParatext "false" @default.
• W1997966062 isRetracted "false" @default.
• W1997966062 magId "1997966062" @default.
• W1997966062 workType "article" @default.